FDA Issues Draft Guidance on OTC Products that Contain Acetaminophen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Issues Draft Guidance on OTC Products that Contain Acetaminophen


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a draft guidance on the labeling of OTC products that contain acetaminophen. The draft guidance would give manufacturers an alternative option to properly clarify the risk of liver damage in OTC acetaminophen-containing products.

The current guidelines require manufacturers of OTC products that contain acetaminophen to include a specific warning on the label that exceeding the maximum daily amount of acetaminophen could cause liver damage. The current language refers to the product’s maximum dosage in terms of dosage units or total amount of tablets in a 24-hour period.

The new draft guidance would give manufacturers the option of stating the maximum daily dosage as 4000 mg. The new language states: “Liver Warning: This product contains acetaminophen. Sever liver damage may occur if you take more than 4000 mg of acetaminophen in 24 hours; with other drugs containing acetaminophen; 3 or more alcoholic drinks every day while using this product.”

According to the draft guidance, FDA “believes that this alternative language should eliminate the potential confusion…and help ensure appropriate dosing of OTC acetaminophen-containing products, while also informing consumers that using more than the currently proposed maximum daily dose of 4000 mg of acetaminophen may result in severe liver damage.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here